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ABSTRACT Naringin, a well-known flavanone glycoside of grapefruit and citrus fruits, was found to be as an effective anti-
inflammatory compound in our previous lipopolysaccharide-induced acute lung injury mouse model via blockading activity of
nuclear factor jB. The current study sought to explore the anti-inflammatory effects of naringin on chronic pulmonary
neutrophilic inflammation in cigarette smoke (CS)-induced rats. Seventy Sprague-Dawley rats were randomly divided into
seven groups to study the effects of CS with or without various concentrations of naringin or saline for 8 weeks. The results
revealed that naringin supplementation at 20, 40, and 80mg/kg significantly increased body weight of CS-induced rats as
compared to that in the CS group. Moreover, naringin of 20, 40, and 80mg/kg prevented CS-induced infiltration of neutrophils
and activation of myeloperoxidase and matrix metalloproteinase-9, in parallel with suppression of the release of cytokines,
such as tumor necrosis factor-a and interleukin-8 (IL-8). IL-10 in bronchoalveolar lavage fluid was significantly suppressed
after CS exposure, but dose dependently elevated by naringin. The results from hematoxylin and eosin staining revealed that
naringin dose dependently reduced CS-induced infiltration of inflammatory cells, thickening of the bronchial wall, and
expansion of average alveolar airspace. In conclusion, our data suggest that naringin is an effective anti-inflammatory
compound for attenuating chronic pulmonary neutrophilic inflammation in CS-induced rats.
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INTRODUCTION
C igarette smoking is the most important risk factor forthe development of inflammatory lung diseases, such as
chronic obstructive pulmonary disease (COPD), which is
characterized by chronic pulmonary inflammation in the
lungs with a progressive and irreversible destruction of small
airways and parenchyma.1,2 It is well established that neu-
trophils adhesion, infiltration, and angiogenic processes are
the important steps in the inflammatory process stimulated
by cigarette smoke (CS), which result from the production and
secretion of many signaling molecules, such as cytokines,
chemokines, and lipid-derived inflammatory mediators.3
The effects of CS exposure have been clearly demon-
strated in large clinical studies, CS-induced rodent models,
and in vitro cell models.4–8 It was demonstrated that oxi-
dative stress caused by CS-exposure increases inflammatory
cell influxes to the lung, which is followed by lipid perox-
idation and increases in proinflammatory cytokine, such as
tumor necrosis factor-a (TNF-a).7 Moreover, interleukin-8
(IL-8) and myeloperoxidase (MPO), predominantly pro-
duced by neutrophils, were found to be elevated in human
bronchial epithelial cells after CS-exposure,9 whereas anti-
inflammatory cytokine of IL-10 was reduced in patients with
bronchial asthma, COPD, and in smokers.10 Matrix me-
talloproteinase-9 (MMP-9), which is the most elastolytic of
the MMPs and predominantly produced by macrophages,
was significantly increased in the lungs of rats induced by
CS and dose dependently attenuated by a selective phos-
phodiesterase 4 (PDE4) inhibitor, Zl-n-91.11 Thus, the CS-
exposure model in rodents might be useful for investigating
anti-inflammatory effects of a novel drug that attenuate
chronic pulmonary inflammation.
Naringin (40,5,7-trihydroxy-flavonone-7-rhamnoglucoside),
a well-known flavanone glycoside of grapefruit and citrus
fruits, has been reported to exhibit antioxidative effects and
inhibit lipid peroxidation in biological membranes.12–13
Moreover, growing evidence has indicated that naringin exerts
anti-inflammatory effects both in vitro and in vivo.12,14–16 It
is well established that naringin significantly prevented lipo-
polysaccharide (LPS)-induced endotoxic shock in mice and
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production of NO in RAW 264.7 macrophage cells.15
Furthermore, our previous study investigated the anti-
inflammatory effects of naringin in an acute pulmonary
inflammatory mouse model with LPS-induced acute lung
injury, and demonstrated that naringin significantly atten-
uated LPS-induced infiltration of inflammatory cells and
the release of proinflammatory cytokines via suppressing
activation of the nuclear factor jB (NF-jB).16 However,
there is no information regarding the effects of naringin on
chronic pulmonary neutrophilic inflammation induced by
CS, which appears to not be affected by treatment with
glucocorticoids as reported in previous studies. Naringin is
an effective cAMP-specific PDE4 inhibitor,17 and accu-
mulating preclinical and clinical evidence suggests that
selective PDE4 inhibitors are effective on inhibition of
pulmonary inflammation and emphysema in COPD animal
model and patients, respectively.11 Thus, the main goal of
the current study was to evaluate the anti-inflammatory
activity of naringin on chronic pulmonary neutrophilic in-
flammation in CS-induced rats.
MATERIALS AND METHODS
Animals
Seventy male and female Sprague-Dawley rats, weighting
between 190–230 g, were obtained from the Guangdong
Medical Laboratory Animal Center (Guangdong, China).
All rats were housed in a temperature (22C – 2C) and
humidity-controlled room with free access to both fresh
water and standard laboratory food. All experimental pro-
cedures were approved by the Animal Care and Use Com-
mittee of the School of Life Sciences, Sun Yat-sen
University (No. 2011082102).
Reagents
The commercial nonfiltered cigarette contains 12mg tar
and 1.2mg nicotine per cigarette (trade name: Ye Shu,
purchased from the Guangdong Tobacco Industrial Co. Ltd.,
Guangdong, China). Naringin was extracted by our laboratory
(extracted from Citrus grandis Tomentosa by water per
ethanol extraction, and purified by 1–10 recrystallizations to
obtain a purity > 98.3% as determined by peak area normal-
ization). Rat TNF-a, IL-8, IL-10, and MMP-9 ELISA Kits
were purchased from R&D Corporation (R&D Systems, Inc.,
Minneapolis, MN,USA).MPO and bicinchoninic acid (BCA)
assay kits were purchased from Jiancheng (Nanjing, China).
Dosage rationale of naringin
C. grandis Tomentosa is a medicinal and edible plant that
contains naringin of 5% to 20% in the dry peel. According to
Chinese Pharmacopoeia, the daily usage and dosage of dry
peel of C. grandis Tomentosa is 3–6 g, which means the daily
intake of naringin for rats is 13.5–108mg/kg. So naringin
dosages from 5 to 80mg/kg were designed in the current study.
Apparatus
The smoking apparatus consists of three major parts, in-
cluding a metal chamber with a glass door, a cigarette
burning with inhalation apparatus, and a ventilation appa-
ratus on the top of the chamber. A 100 cm (length) · 60 cm
(width)· 60 cm (height) metal chamber separated into two
layers with sufficient space for exposing 24 rats at a time.
The cigarette burner contained 12 cigarette holders, a plastic
wye injection casing, and a 300-mL glass injector, which
could burn up 12 cigarettes in 3min at a time and inject CS
into the chamber by manual control of one-way valves. The
ventilation apparatus would pump out all of the CS in the
chamber within 15min after exposure. During the experi-
ment, temperature in the chamber was kept between 19C–
23C with the help of a condensation interlayer, carbon
monoxide was controlled between 310–380 ppm, carbon
dioxide was controlled between 10415–11406 ppm, oxygen
was kept between 19.2%–20.5%, and total suspended par-
ticles was kept between 70 and 110mg/m3.
Animal administration and modeling procedures
Rats were randomly divided into the following seven groups
and dealt with the following steps, respectively (n=10).
Group a: Con group. Animals were placed into the same
type of apparatus as described in CS-induced group, and
exposed to fresh air instead of CS for 8 weeks.
Group b: CS group. Animals were placed into the chamber
and exposed to successive periods of CS for 1 h in the
morning and 1 h in the afternoon, 7 days a week. The amount
of cigarette exposure was increased as follows: 3 cigarettes on
the 1st day, 7 cigarettes on the 2nd day, 12 cigarettes on the
3rd to 5th day (30min at each time), and 12 cigarettes on the
6th day (1 h at each time) to the end of 8 weeks.
Group c: CS +Nar1 group, Group d: CS+Nar2 group,
Group e: CS+Nar3 group, Group f: CS+Nar4 group, and
Group g: CS +Nar5 group. Rats in these groups were ex-
posed to CS as described in the CS group above. One hour
before the first CS exposure on each day, animals were in-
tragastricaly administered with naringin of 5, 10, 20, 40, or
80mg/kg, respectively.
On each 7th day, bodyweights of rats in each group were
weighed by electronic balance after 12 h fasting. Feed intake
in each group was weighed by the weight loss method on the
morning of every day.
Analysis of immunocytes and cytokines
in bronchoalveolar lavage fluid
Fourteen hours after the last exposure to CS, animals were
anesthetized with chloral hydrate (3.5%) and sacrificed by
heart bloodletting using vacuum tubes from the left side of
heart. Trachea and chest of rats were surgically exposed, and
then a gavage needle (No. 16) was inserted into the trachea.
The left lung lobes were ligated, while the right lung lobes
were used for lavage. The bronchoalveolar lavage fluid
(BALF) was performed as previously reported.16 After
centrifuging the BALF samples for 10min (3000 g, 4C),
the sediment cells were resuspended in 0.5mL PBS and
counted by ABXMICROS 60. The supernatants were stored
at - 20C until used for analysis of TNF-a, IL-8, and IL-10
according to the manufacturer’s instructions.
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Analysis of MPO and MMP-9 activities in lung tissue
Lung MPO activity was measured using the colorimetric
method with a UV-VIS spectrophotometer (TU-1901, Pur-
kinje General Instrument Co., Ltd., Beijing, China), using a
commercial MPO assay kit. Total protein was extracted
from the lung tissue by the RIPA lysate (Beyotime,
Shanghai, China) and measured with the BCA assay kit
according to standard steps. Then, the content of MMP-9 in
the tissue lysate was analyzed by ELISA.
Lung histological examination
by hematoxylin and eosin staining
The left lung lobes and the remaining trachea of rats were
then removed and perfusion fixed via a tracheal cannula
with 10% neutral formalin at a hydrostatic pressure of 20 cm
H2O. After 10min, the trachea was ligated and the lung was
immersed in 10% neutral formalin for 7 days. After fixation,
the left lung lobes were imbedded in paraffin wax and cut
into sections of 3–4lm, and then suitable sections were
selected and stained with hematoxylin and eosin (H&E) for
histological examination. Slides were scanned with a Mirax
Scan (Carl Zeiss MicroImaging GmbH, Go¨ttingen, Ger-
many) at ·100 and ·400 magnifications, At least two
nonconsecutive slides per block were analyzed for influx of
inflammatory cells, average alveolar airspace, and thickness
of bronchial wall by corresponding Mirax Viewer software
as previously described.18
Statistical analysis
Unless otherwise stated, data are presented as mean –
S.D. Analysis of variance was used to compare experimental
animals to control group, while comparisons between mul-
tiple groups were performed using the Tukey’s Multiple
Comparison test. For all experiments, P < .05 was taken as
statistically significant.
RESULTS
Effect of naringin on CS-induced body
weight changes of rats
As shown in Figure 1, although the initial body
weight was similar between all groups, the rats in the CS
group weighed significantly less than those rats in the Con
group after the 8-week exposure period. After the 8-week
exposure, the body weight of rats in the Con group in-
creased to 351.4 – 81.7 g, whereas the CS group rats en-
hanced to 271.7 – 65.4 g only, which means the loss ratio
of body weight was 60.7% as compared with the Con
group. The body weight of CS-induced animals treated
with 5 and 10mg/kg naringin showed no significant dif-
ferences as compared to that in the CS group. However,
body weight of CS-induced rats treated with naringin of
20, 40, and 80mg/kg elicited a pronounced increase as
compared to that in the CS group after 8 weeks of CS
exposure.
Effect of naringin on CS-induced influx
of leukocytes in BALF of rats
As shown in Table 1, the number of total leukocytes in
BALF of CS group rats was significantly increased to 4.0-
fold as compared to that in the Con group. Naringin dose
dependently attenuated CS-induced influx of leukocytes in
BALF. The total leukocytes in BALF of CS-induced rats
treated with naringin of 20, 40, and 80mg/kg elicited a
pronounced decrease as compared to that in the CS group
after 8 weeks of CS exposure. Moreover, the percentage of
neutrophils in the BALF of CS group rats was significantly
increased to 2.9-fold as compared to that in the Con group,
while percentages of macrophages and lymphocytes par-
tially, but not significantly, decreased suggesting that there
is a remarkable chronic pulmonary neutrophilic inflamma-
tion after 8 weeks of CS exposure. Naringin of 20, 40, and
80mg/kg significantly reduced the percentage of neutrophils
in BALF of CS-induced rats. As compared with CS group
rats, the number of neutrophils, macrophages, and lym-
phocytes in BALF of rats treated with naringin of 80mg/kg
was significantly decreased by 84.6%, 49.5%, and 61.8%,
respectively.
Effect of naringin on CS-induced release
of TNF-a, IL-8, and IL-10 in BALF of rats
Release of inflammatory mediators was additionally de-
termined in BALF. As shown in Table 2, after 8 weeks of CS
exposure, the contents of TNF-a and IL-8 in BALF were
significantly elevated to 2.9- and 2.1-fold, respectively.
Moreover, Naringin dose dependently reduced CS-induced
release of TNF-a and IL-8. At the highest tested dose
of naringin (80mg/kg), maximum inhibition for TNF-a and
IL-8 was 73.9% and 101.1%, respectively.
Otherwise, content of IL-10 in BALF was markedly de-
creased by 55.5% after 8 weeks of CS exposure, but dose
dependently elevated after treated with naringin. In the
group of rats treated with naringin of 80mg/kg, the content
of IL-10 was slightly higher than that in the Con group.
FIG. 1. Effect of naringin on cigarette smoke (CS)–induced body
weight changes of rats. Rats were repeatedly exposed to CS or fresh
air (control [Con] group) for 8 weeks, the body weight of rats was
weighed on each 7th day after 12-h fasting. Data are given as mean
(n = 8–10; value of S.D. is omitted). Significant differences were
found: **P< .01 compared with the control group; #P < .05, ##P < .01
compared with the CS group.
896 NIE ET AL.
Effect of naringin on CS-induced release
of MPO and MMP-9 in lung tissue of rats
MPO, as an important proinflammatory and pro-oxidant
mediator, is mainly released from activated neutrophils.9 As
shown in Table 3, activity of MPO in the lungs of CS group
rats was significantly increased to 3.4-fold as compared to
that in the Con group. Naringin of 10, 20, 40, and 80mg/kg
significantly inhibited the activity of MPO in the lungs of
CS-induced rats, with inhibition rates of 51.0% to 86.5%.
MMP-9, mainly secreted by lung macrophages, is con-
sidered an osteolytic enzyme and has been associated with
loss of pulmonary elastin levels and adult onset emphysema
in COPD.11 As shown in Table 3, content of MMP-9 in the
Table 1. Naringin Attenuates Cigarette Smoke-Induced Influx of Leukocytes in Bronchoalveolar Lavage Fluid of Rats
Differential leukocytes (%)
Group Dose (mg/kg)
Total leukocytes
( · 108/L) Neutrophils
Mononuclear
macrophages Lymphocytes
Control 1.45 – 0.46 12.54– 5.42 50.84 – 13.34 29.87– 10.31
CS 5.83 – 0.99** 36.13– 19.26** 35.92 – 15.85 18.37– 15.69
CS +Nar1 5 5.14 – 1.45** 30.89– 9.62** 36.89 – 15.43 22.28– 5.85
CS +Nar2 10 4.32 – 0.61** 29.21– 14.67* 38.80 – 10.16 23.12– 15.37
CS +Nar3 20 3.44 – 1.31**,# 21.16– 13.34# 44.23 – 15.58 22.97– 18.79
CS +Nar4 40 2.92 – 0.49*,## 18.74– 4.54## 50.50 – 13.73 20.83– 6.82
CS +Nar5 80 2.87 – 0.37*,## 16.63– 9.42## 49.55 – 17.58 23.68– 12.56
Data are presented as mean– SD (n= 8–10).
Significant differences were found: *P< .05, **P < .01 compared with normal control group; #P < .05, ##P < .01 compared with cigarette smoke (CS) group.
Nar1–5, Naringin (5, 10, 20, 40, and 80mg/kg).
Table 2. Effects of Naringin on Cigarette Smoke–Induced Release of Tumor Necrosis Factor-a, Interleukin-8,
and Interleukin-10 in Bronchoalveolar Lavage Fluid of Rats
TNF-a IL-8 IL-10
Group C (pg/mL) IR C (pg/mL) IR C (pg/mL) GR
Control 1.97 – 0.28 1.78 – 0.42 25.4 – 0.40
CS 5.66 – 1.02** 3.84 – 0.67** 11.3 – 1.92**
CS +Nar1 5.10 – 0.74 15.0% 3.21 – 0.84# 30.7% 13.7 – 1.57 21.2%
CS +Nar2 4.12 – 0.64# 41.4% 2.63 – 0.48## 58.9% 17.4 – 1.31## 54.0%
CS +Nar3 3.50 – 0.39## 58.6% 2.30 – 0.63## 75.4% 21.8 – 1.10## 92.9%
CS +Nar4 3.18 – 0.72## 67.2% 2.09 – 0.47## 85.0% 27.9 – 1.52## 146.9%
CS +Nar5 2.94 – 0.53## 73.9% 1.77 – 0.92## 101.1% 29.3 – 1.62## 159.3%
Data are presented as mean– SD (n= 8–10).
Significant differences were found: **P< .01 compared with normal control group; #P< .05, ##P< .01 compared with CS group.
C, contents; IR, inhibition rate; GR, growth rate; IL, interleukin; TNF-a, tumor necrosis factor-a.
Table 3. Effects of Naringin on Cigarette Smoke–Induced Release of Myeloperoxidase
and Matrix Metalloproteinase-9 in Lung Tissue of Rats
MPO MMP-9
Group Dose (mg/kg) Activation (U/g tissue) IR Contents (ng/g protein) IR
Control 2.41 – 0.37 17.4 – 4.7
CS 8.07 – 1.91** 39.7 – 4.8**
CS +Nar1 5 7.07 – 1.11 17.7% 35.2 – 7.1 20.2%
CS +Nar2 10 5.18 – 1.67## 51.0% 33.7 – 6.4# 26.9%
CS +Nar3 20 3.99 – 0.82## 72.0% 29.4 – 4.1## 46.2%
CS +Nar4 40 3.49 – 1.21## 80.8% 27.5 – 5.8## 54.7%
CS +Nar5 80 3.17 – 1.74## 86.5% 25.3 – 3.4## 64.6%
Data are presented as mean– SD (n= 8–10).
Significant differences were found: **P< .01 compared with normal control group; #P< .05, ##P< .01 compared with CS group.
MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase.
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lung tissue of the CS group was significantly increased to
2.3-fold as compared to that in the Con group. Naringin of
10, 20, 40, and 80mg/kg significantly inhibited the content
of MMP-9 in lung tissue lysate of CS-induced rats, with
inhibition rates of 26.9% to 64.6%.
Effect of naringin on CS-induced histological changes
To investigate the effects of naringin treatment on the
infiltration of inflammatory cells, average alveolar airspace,
and thickness of bronchial wall, lung sections were prepared
and observed by H&E staining. As shown in Figure 2, the
lung section of the Con group showed a normal bronch-
oalveolar structure with few infiltration of inflammatory
cells, average alveolar airspace of appropriate 90lm2, as
well as bronchial wall thickness of nearly 29lm. CS ex-
posure markedly induced influx of inflammatory cells,
thickening of bronchial wall, and expansion of average al-
veolar airspace. Moreover, naringin dose dependently re-
duced CS-induced infiltration of inflammatory cells,
thickening of bronchial wall, and expansion of alveolar
airspace, especially at doses of 20, 40, and 80mg/kg, which
exhibited significant differences as compared to that in the
CS group. These results suggested that naringin could at-
tenuate CS-induced damage of lung tissue by reducing the
infiltration of inflammatory cells, expansion of alveolar
airspace, as well as weakening the secretion and prolifera-
tion of airway epithelium.
DISCUSSION
Various models of CS exposure in laboratory rats have
been described over the years.2–6 It is demonstrated that CS
exposure directly damages the airway epithelium and acti-
vates macrophages and lymphocytes, which then generate
preinflammatory cytokines TNF-a and IL-8, and activate
neutrophils, which leads to chronic pulmonary neutrophilic
inflammation.7 Moreover, the neutrophils help recruit
macrophages, which secretes MMP-9 and a number of in-
flammatory cytokines contributing to the pathogenic nature
of macrophages.19 Our CS-induced rat model showed
characteristic pathological changes consistent with chronic
pulmonary neutrophilic inflammation. Moreover, our study
demonstrated that naringin significantly reduced the infil-
tration of neutrophils and both activities of MPO and
MMP-9 in the lung of CS-induced rats, which in parallel
FIG. 2. Effect of naringin on CS-in-
duced histological changes. The left
lung lobes of rats were stained by he-
matoxylin and eosin. Slides were
scanned at · 100 magnification. (a)
Con group, (b) CS group, (c) CS +
Nar1 group, (d) CS +Nar2 group, (e)
CS +Nar3 group, (f) CS +Nar4 group,
(gc): CS +Nar5 group, (h) influx of
inflammatory cells, (i) average alveolar
airspace, and (j) thickness of bronchial
wall. Data are given as mean– SD
(n= 3). Significant differences were
found: **P< .01 compared with the
control group; #P < .05, ##P < .01 com-
pared with the CS group. Color images
available online at www.liebertpub
.com/jmf
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with the suppression in the release of cytokines, such as
TNF-a and IL-8. These results suggest that naringin pre-
vents the inflammation induced by CS, probably through
regulation of these signal molecules.
The body weight of naringin-treated rats was greater than
CS-induced rats after 8 weeks of CS exposure. This was
probably because naringin prevented lung inflammation, as
previous studies demonstrate that severe lung inflammation
in mice caused by CS exposure is associated with weight
loss.20 Moreover, the feed intake in each group was weighed
on the morning of each day. Our results showed that at the
highest tested dose of naringin (80mg/kg), the feed intake of
rats was increased by 21.4% as compared to that in the CS
group (data not shown).
As previous studies describe, oxidants and MMPs
complement each other in the potential to destroy lung
tissue.21–23 Moreover, it is reported that MMPs also play a
role in regulating inflammation through the generation of
cytokines, such as TNF-a.24 We observed that the increase
of MMP-9 activity in the CS group was associated with
expansion of average alveolar airspace after exposure to CS
for 8 weeks. Moreover, CS-induced rats treated with nar-
ingin of 20, 40, and 80mg/kg displayed lower MMP-9 ac-
tivity and smaller alveolar airspace, probably due to less cell
inflammatory influx into the airspace, and the suppression of
oxidative stress provoked by CS.
Clinical studies have shown that IL-10 was reduced in
patients of bronchial asthma and COPD.25 Moreover, IL-10
was reported to inhibit the secretion of TNF-a and IL-8 from
macrophages and tip the balance in favor of antiproteases by
increasing the expression of endogenous tissue inhibitors of
MMPs.26 In the present study, we demonstrated that CS
exposure significantly inhibited the release of IL-10, which
was associated with previous clinical studies. Moreover,
naringin of 80mg/kg markedly elevated the release of IL-10,
as well as strongly suppressed the activity of NF-jB.16
Previous reports have revealed that IL-10 was very effective
at inhibiting the activity of NF-jB.27 This means that IL-10
should suppress the CS-induced activity of NF-jB, which
reduces release of proinflammatory cytokines and infiltra-
tion of inflammatory cells.
In conclusion, our study demonstrated that the infiltration
of inflammatory cells, activation of MPO and MMP-9, and
increases in TNF-a and IL-8 in the lungs of CS-induced rats
were associated with decreased IL-10. In this study, naringin
at doses 20, 40, and 80mg/kg elevated the release of IL-10,
prevented the infiltration of neutrophils, and decreased ac-
tivities of MPO and MMP-9, which resulted in the sup-
pression of TNF-a and IL-8 release. Our data suggest that
naringin is an effective anti-inflammatory compound to at-
tenuate chronic pulmonary neutrophilic inflammation in CS-
induced rats.
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